**Claims**

1. A compound, or pharmaceutically acceptable salt thereof, having the structure of Formula I:



,

Formula I

wherein A is optionally substituted 3 to 6-membered heterocycloalkylene, optionally substituted 3 to 6-membered cycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5 to 10-membered heteroarylene;

W is a cross-linking group comprising an aziridine, an epoxide, a carbodiimide, an oxazoline, a thiazoline, a chloroethyl urea, a chloroethyl thiourea, a chloroethyl carbamate, a chloroethyl thiocarbamate, a trifluoromethyl ketone, a boronic acid, a boronic ester, an N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), an iso-EEDQ or other EEDQ derivative, an oxazolium, or a glycal;

$X^1$ is $CH_2$ or O;

m is 1 or 2;

n is 0 or 1;

$R^1$ is hydrogen or optionally substituted 3 to 10-membered heterocycloalkyl;

$R^2$ is optionally substituted $C_1$-$C_6$ alkyl; and

$R^3$ is optionally substituted $C_1$-$C_6$ alkyl or optionally substituted 3 to 6-membered cycloalkyl.

2. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein A is optionally substituted thiazole, optionally substituted oxazole, optionally substituted morpholino, optionally substituted pyrrolidinyl, optionally substituted piperidinyl, or optionally substituted phenyl.

3. The compound of claim 1 or claim 2, or pharmaceutically acceptable salt thereof, wherein $R^2$ is:  or .

4. The compound of any one of claims 1 to 3, or pharmaceutically acceptable salt thereof, wherein $R^3$ is optionally substituted $C_1$-$C_6$ alkyl.

5. The compound of any one of claims 1 to 3, or pharmaceutically acceptable salt thereof, wherein $R^3$ is or optionally substituted 3 to 6-membered cycloalkyl.

6. The compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof, wherein A is optionally substituted 5 to 10-membered heteroarylene.

7. The compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof, wherein A is optionally substituted phenyl.

8. The compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof, wherein A is optionally substituted 3 to 6-membered heterocycloalkylene.

9. The compound of any one of claims 1 to 8, or pharmaceutically acceptable salt thereof, wherein W comprises an aziridine.

10. The compound of claim 9, or pharmaceutically acceptable salt thereof, wherein W comprises an optionally substituted cyclopropyl-aziridinyl moiety.

11. The compound of any one of claims 1 to 8, or pharmaceutically acceptable salt thereof, wherein W comprises an epoxide.

12. The compound of any one of claims 1 to 11, or pharmaceutically acceptable salt thereof, having the structure of a compound of Table 1 as shown hereafter:

| Ex# | Structure |
|---|---|
| A1 |  |
| A2 |  |

| | |
|---|---|
| A3 |  |
| A4 |  |
| A5 |  |
| A6 |  |

| | |
|---|---|
| A7 |  |
| A8 |  |
| A9 |  |
| A10 |  |

| | |
|---|---|
| A11 |  |
| A12 |  |
| A13 |  |
| A14 |  |

| | |
|---|---|
| A15 |  |
| A16 |  |
| A17 |  |
| A18 |  |

| | |
|---|---|
| A19 |  |
| A20 |  |
| A21 |  |
| A22 |  |

| | |
|---|---|
| A23 |  |
| A24 |  |
| A25 |  |

| | |
|---|---|
| A26 |  |
| A27 |  |
| A28 |  |

| | |
|---|---|
| A29 |  |
| A30 |  |
| A31 |  |

| | |
|---|---|
| A32 |  |
| A33 |  |
| A34 |  |

| | |
|---|---|
| A35 |  |
| A36 |  |
| A37 |  |

| | |
|---|---|
| A38 |  |
| A39 |  |
| A40 |  |

| | |
|---|---|
| A41 |  |
| A42 |  |
| A43 |  |
| A44 |  |

, or having the structure of a compound of Table 2 as shown hereafter:

| Ex# | Structure |
|---|---|

| | |
|---|---|
| B1 |  |
| B2 |  |
| B3 |  |

| | |
|---|---|
| B4 |  |
| B5 |  |
| B6 |  |
| B7 |  |

| | |
|---|---|
| B8 |  |
| B9 |  |
| B10 |  |

| | |
|---|---|
| B11 |  |
| B12 |  |
| B13 |  |

| | |
|---|---|
| B14 |  |
| B15 |  |
| B16 |  |
| B17 |  |

| | |
|---|---|
| B18 |  |
| B19 |  |
| B20 |  |
| B21 |  |

| | |
|---|---|
| B22 |  |
| B23 |  |
| B24 |  |
| B25 |  |

| | |
|---|---|
| B26 |  |
| B27 |  |
| B28 |  |
| B29 |  |

| | |
|---|---|
| B30 |  |
| B31 |  |
| B32 |  |
| B33 |  |

| | |
|---|---|
| B34 |  |
| B35 |  |
| B36 |  |
| B37 |  |

| | |
|---|---|
| B38 |  |
| B39 |  |
| B40 |  |
| B41 |  |

| | |
|---|---|
| B42 |  |
| B43 |  |
| B44 |  |
| B45 |  |

| | |
|---|---|
| B46 |  |
| B47 |  |
| B48 |  |
| B49 |  |

| | |
|---|---|
| B50 |  |
| B51 |  |
| B52 |  |
| B53 |  |

| | |
|---|---|
| **B54** |  |
| **B55** |  |
| **B56** |  |
| **B57** |  |

| | |
|---|---|
| B58 |  |
| B59 |  |
| B60 |  |

| | |
|---|---|
| B61 |  |
| B62 |  |
| B63 |  |
| B64 |  |

| | |
|---|---|
| B65 |  |
| B66 |  |
| B67 |  |
| B68 |  |

| | |
|---|---|
| B69 |  |
| B70 |  |
| B71 |  |
| B72 |  |

| | |
|---|---|
| B73 |  |
| B74 |  |
| B75 |  |
| B76 |  |

| | |
|---|---|
| B77 |  |
| B78 |  |
| B79 |  |
| B80 |  |

| | |
|---|---|
| B81 |  |
| B82 |  |
| B83 |  |
| B84 |  |

| | |
|---|---|
| B85 |  |
| B86 |  |
| B87 |  |

| | |
|---|---|
| B88 |  |
| B89 |  |
| B90 |  |
| B91 |  |

| | |
|---|---|
| B92 |  |
| B93 |  |
| B94 |  |
| B95 |  |

| | |
|---|---|
| B96 |  |
| B97 |  |
| B98 |  |
| B99 |  |

| | |
|---|---|
| **B100** |  |
| **B101** |  |
| **B102** |  |
| **B103** |  |

| | |
|---|---|
| **B104** |  |
| **B105** |  |
| **B106** |  |
| **B107** |  |

| | |
|---|---|
| **B108** |  |
| **B109** |  |
| **B110** |  |
| **B111** |  |

| | |
|---|---|
| B112 |  |
| B113 |  |
| B114 |  |
| B115 |  |

| | |
|---|---|
| B116 |  |
| B117 |  |
| B118 |  |
| B119 |  |

.

13. A compound, or pharmaceutically acceptable salt thereof, having the structure of Formula III:



,

Formula III

wherein P is -(CO)$R^9$, -(PO)$(OH)_2$, or -Si$(R^{10})_3$;

W is a cross-linking group comprising an aziridine, an epoxide, a carbodiimide, an oxazoline, a thiazoline, a chloroethyl urea, a chloroethyl thiourea, a chloroethyl carbamate, a chloroethyl thiocarbamate, a trifluoromethyl ketone, a boronic acid, a boronic ester, an N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), an iso-EEDQ or other EEDQ derivative, an oxazolium, or a glycal;

$L^1$ is optionally substituted 3 to 9-membered heterocycloalkylene or optionally substituted $C_2$-$C_4$ heteroalkylene;

$R^4$ is optionally substituted $C_1$-$C_6$ alkyl;

$R^5$ is optionally substituted $C_1$-$C_6$ alkyl or optionally substituted 3 to 6-membered cycloalkyl;

$R^9$ is optionally substituted $C_1$-$C_3$ alkyl or optionally substituted $C_1$-$C_3$ heteroalkyl; and

each $R^{10}$ is, independently, optionally substituted $C_1$-$C_3$ alkyl.

14. The compound of claim 13, or pharmaceutically acceptable salt thereof, having the structure of a compound of Table 3 as shown hereafter:

| Ex# | Structure |
|---|---|
| C1 |  |

| | |
|---|---|
| C2 |  |
| C3 |  |
| C4 |  |
| C5 |  |

| | |
|---|---|
| C6 |  |
| C7 |  |
| C8 |  |
| C9 |  |

, or having the structure of a compound of Table 4 as shown hereafter:

| Ex# | Structure |
|---|---|
| D1 |  |
| D2 |  |
| D3 |  |
| D4 |  |

| | |
|---|---|
| D5 |  |
| D6 |  |

.

15. A compound, or pharmaceutically acceptable salt thereof, having the structure of a compound of Table 5 as shown hereafter:

| Ex# | Structure |
|---|---|
| E1 |  |
| E2 |  |
| E3 |  |

| | |
|---|---|
| E4 |  |

.

16. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of any one of claims 1 to 15 and a pharmaceutically acceptable excipient.

17. A conjugate, or salt thereof, comprising the structure of Formula IV:

$M\text{-}L^2\text{-}P^1$

Formula IV

wherein $L^2$ is a linker;

$P^1$ is a monovalent organic moiety; and

M has the structure of Formula V:



Formula V,

wherein A is optionally substituted 3 to 6-membered heterocycloalkylene, optionally substituted 3 to 6-membered cycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5 to 10-membered heteroarylene;

$X^1$ is $CH_2$ or O;

m is 1 or 2;

n is 0 or 1;

$R^1$ is hydrogen or optionally substituted 3 to 10-membered heterocycloalkyl;

$R^2$ is optionally substituted $C_1$-$C_6$ alkyl; and

$R^3$ is optionally substituted $C_1$-$C_6$ alkyl or optionally substituted 3 to 6-membered cycloalkyl.

18. Use of a compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 16, in the manufacture of a medicament for treating cancer.

19. Use of a compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 16, in the manufacture of a medicament for treating a Ras protein-related disorder in a subject in need thereof.

20. An *in vitro* or *ex vivo* method of inhibiting a Ras protein in a cell, the method comprising contacting the cell with an effective amount of a compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 16.

21. A compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 16, for use in therapy.